Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial
Wise RA, Holbrook JT, Criner G, Sethi S, Rayapudi S, Sudini KR, Sugar EA, Burke A, Thimmulappa R, Singh A, Talalay P, Fahey JW, Berenson CS, Jacobs MR, Biswal S, Broccoli Sprout Extract Trial Research Group
PloS one · 101 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Heart, Lung, and Blood Institute
- Gobierno
- NHLBI NIH HHS
- Subvenciones
- National Heart, Lung, and Blood Institute (U01 HL105569); National Heart, Lung, and Blood Institute (5U01HL105569)
Según 2 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2016-11-10 · PLoS One · vol. 11 · número 11 · pág. e0163716
- Editorial
- Public Library of Science
- Citado
- 121 citas · más que el 96% de estudios similares · 5.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 33 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Genomics, phytochemicals, and oxidative stress · Curcumin's Biomedical Applications · Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Palabras clave
- Sulforaphane, COPD, Placebo, Medicine, Oxidative stress, Inflammation, Internal medicine, Randomized controlled trial, Pulmonary function testing, Immunology, Gastroenterology, Pathology, Cancer research
- MeSH
- humans, pulmonary disease, chronic obstructive, isothiocyanates, sulfoxides, administration, oral, double-blind method, gene expression regulation, oxidative stress, aged, middle aged, female, male, nf-e2-related factor 2
15 autores
- Robert A. Wise🇺🇸 · autor de correspondenciaJohns Hopkins University; Johns Hopkins Medicine
- Janet T. Holbrook🇺🇸Johns Hopkins University
- Gerard J. Criner🇺🇸Temple University
- Sanjay Sethi🇺🇸VA Western New York Healthcare System
- Sobharani Rayapudi🇺🇸Johns Hopkins University
- Kuladeep R. Sudini🇺🇸Johns Hopkins University
- Elizabeth A. Sugar🇺🇸Johns Hopkins University
- Alyce E. Burke🇺🇸Johns Hopkins University
- Rajesh Kumar Thimmulappa🇺🇸Johns Hopkins University
- Anju Singh🇺🇸Johns Hopkins University
- Paul Talalay🇺🇸Johns Hopkins University; Johns Hopkins Medicine
- Jed W. Fahey🇺🇸Johns Hopkins University; Johns Hopkins Medicine
- Charles S. Berenson🇺🇸VA Western New York Healthcare System
- Michael R. Jacobs🇺🇸Temple University
- Shyam S. Biswal🇺🇸Johns Hopkins University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
COPD patients have high pulmonary and systemic oxidative stress that correlates with severity of disease. Sulforaphane has been shown to induce expression of antioxidant genes via activation of a transcription factor, nuclear factor erythroid-2 related factor 2 (Nrf2).
Methods
This parallel, placebo-controlled, phase 2, randomized trial was conducted at three US academic medical centers. Patients who met GOLD criteria for COPD and were able to tolerate bronchoscopies were randomly assigned (1:1:1) to receive placebo, 25 μmoles, or 150 μmoles sulforaphane daily by mouth for four weeks. The primary outcomes were changes in Nrf2 target gene expression (NQ01, HO1, AKR1C1 and AKR1C3) in alveolar macrophages and bronchial epithelial cells. Secondary outcomes included measures of oxidative stress and airway inflammation, and pulmonary function tests.
Results
Between July 2011 and May 2013, 89 patients were enrolled and randomized. Sulforaphane was absorbed in the patients as evident from their plasma metabolite levels. Changes in Nrf2 target gene expression relative to baseline ranged from 0.79 to 1.45 and there was no consistent pattern among the three groups; the changes were not statistically significantly different from baseline. Changes in measures of inflammation and pulmonary function tests were not different among the groups. Sulforaphane was well tolerated at both dose levels.
Conclusion
Sulforaphane administered for four weeks at doses of 25 μmoles and 150 μmoles to patients with COPD did not stimulate the expression of Nrf2 target genes or have an effect on levels of other anti-oxidants or markers of inflammation.
Trial registration
Clinicaltrials.gov: NCT01335971.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC0).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.